GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Monash IVF Group Ltd (ASX:MVF) » Definitions » EV-to-EBITDA

Monash IVF Group (ASX:MVF) EV-to-EBITDA : 13.22 (As of Apr. 30, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Monash IVF Group EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Monash IVF Group's enterprise value is A$686.6 Mil. Monash IVF Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$51.9 Mil. Therefore, Monash IVF Group's EV-to-EBITDA for today is 13.22.

The historical rank and industry rank for Monash IVF Group's EV-to-EBITDA or its related term are showing as below:

ASX:MVF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.01   Med: 10   Max: 14.57
Current: 13.22

During the past 10 years, the highest EV-to-EBITDA of Monash IVF Group was 14.57. The lowest was 5.01. And the median was 10.00.

ASX:MVF's EV-to-EBITDA is ranked better than
56.3% of 119 companies
in the Medical Diagnostics & Research industry
Industry Median: 15.41 vs ASX:MVF: 13.22

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-30), Monash IVF Group's stock price is A$1.465. Monash IVF Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.062. Therefore, Monash IVF Group's PE Ratio for today is 23.63.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Monash IVF Group EV-to-EBITDA Historical Data

The historical data trend for Monash IVF Group's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Monash IVF Group EV-to-EBITDA Chart

Monash IVF Group Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.34 7.90 7.43 10.56 11.64

Monash IVF Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 10.56 - 11.64 -

Competitive Comparison of Monash IVF Group's EV-to-EBITDA

For the Diagnostics & Research subindustry, Monash IVF Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Monash IVF Group's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Monash IVF Group's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Monash IVF Group's EV-to-EBITDA falls into.



Monash IVF Group EV-to-EBITDA Calculation

Monash IVF Group's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=686.628/51.932
=13.22

Monash IVF Group's current Enterprise Value is A$686.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Monash IVF Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$51.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Monash IVF Group  (ASX:MVF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Monash IVF Group's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.465/0.062
=23.63

Monash IVF Group's share price for today is A$1.465.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Monash IVF Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.062.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Monash IVF Group EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Monash IVF Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Monash IVF Group (ASX:MVF) Business Description

Traded in Other Exchanges
Address
510 Church Street, Level 1, Cremorne, Cremorne, VIC, AUS, 3121
Monash IVF Group Ltd is a specialist assisted reproductive services provider. The company offers specialist diagnostic obstetric and gynaecological ultrasound and fertility treatments. The company's operating segment includes Australia and International. It generates maximum revenue from the Australian segment. Australian segment is a provider of Assisted Reproductive Services, Ultrasound, and other related services. The International segment is a provider of Assisted Reproductive Services in Malaysia.